Monopar (MNPR): Buy the Approved-Probability Upside in Wilson Disease - Initiate Long
Monopar (MNPR) is a small-cap biotech with a lead late-stage asset for Wilson disease, ALXN1840. Positive Phase 3 signals, supportive Phase 2 histology and neurologic readouts, and an NDA on track for mid-2026 create a near-term regulatory catalyst. With market cap ~$729M versus reported cash runway through 2027, the stock is positioned for a mater…